Christina Yfanti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christina Yfanti has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Alexandros Sotiriadis
2nd Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, GRC
2 shared publicationsAlexandros Traianos
Second Department of Obstetrics and Gynecology of Thessaloniki, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
2 shared publicationsApostolos Sidiropoulos
Second Department of Obstetrics and Gynecology of Thessaloniki, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
2 shared publicationsChrysoula Margioula-Siarkou
Second Department of Obstetrics and Gynecology of Thessaloniki, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
2 shared publicationsEffrosyni Styliara
Department of Radiology, University Hospital of Ioannina, Medical School, Ioannina, Greece
2 shared publicationsElif Empliouk
2nd Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, GRC
2 shared publications
Latest Publications
- Open Access
Lactate Dehydrogenase-5 and Tumor-Infiltrating Lymphocytes in Prostate Cancer Patients Undergoing Radical Hypofractionated Radiotherapy
Background/Objectives: Aerobic glycolysis is a standard mechanism that cancer cells use to support their anabolic processes. Lactate and proton production, byproducts of this LDHA-catalyzed transformation of pyruvate, may contribute to acidifying the tumor microenvironment and to repressing the cytotoxic activity of anti-tumor immune cells. Prostate cancer radiotherapy outcome could be diminished by cancer cell metabolism and immunosuppression. Methods: The tumor infiltrating lymphocyte (TIL) density was assessed in 110 prostate adenocarcinoma biopsies from patients treated with radical radiotherapy. Immunohistochemistry was performed to evaluate LDH5 expression by cancer cells (encoded by the LDHA gene). Results: Higher tumor stages (T3 and T4) were associated with lower TIL density (p = 0.02). Approximately half of the patients (51%) displayed strong LDH5 cancer cell expression, which was linked with advanced T-stage and higher Gleason scores (p = 0.05 and p = 0.01, respectively). High LDH5 expression was significantly correlated with low TIL density (p ≤ 0.0004). In univariate analysis, high LDH5 and low TIL density were associated with poor biochemical relapse-free survival (BRFS) (p ≤ 0.006). In multivariate analysis, TIL density, but not LDH5, was an independent predictor of BRFS (p = 0.03). Conclusions: LDH5 overexpression is associated with low tumor lymphocytic infiltration. Stratifying prostate carcinomas according to LDH5/TIL density identifies a group of patients with low TIL density and high LDH5 expression, who have a higher risk of tumor relapse. Targeting glycolysis to disrupt cancer cell metabolism offers an interesting research area for prostate cancer therapy.
Open AccessLactate Dehydrogenase-5 and Tumor-Infiltrating Lymphocytes in Prostate Cancer Patients Undergoing Radical Hypofractionated Radiotherapy
Background/Objectives: Aerobic glycolysis is a standard mechanism that cancer cells use to support their anabolic processes. Lactate and proton production, byproducts of this LDHA-catalyzed transformation of pyruvate, may contribute to acidifying the tumor microenvironment and to repressing the cytotoxic activity of anti-tumor immune cells. Prostate cancer radiotherapy outcome could be diminished by cancer cell metabolism and immunosuppression. Methods: The tumor infiltrating lymphocyte (TIL) density was assessed in 110 prostate adenocarcinoma biopsies from patients treated with radical radiotherapy. Immunohistochemistry was performed to evaluate LDH5 expression by cancer cells (encoded by the LDHA gene). Results: Higher tumor stages (T3 and T4) were associated with lower TIL density (p = 0.02). Approximately half of the patients (51%) displayed strong LDH5 cancer cell expression, which was linked with advanced T-stage and higher Gleason scores (p = 0.05 and p = 0.01, respectively). High LDH5 expression was significantly correlated with low TIL density (p ≤ 0.0004). In univariate analysis, high LDH5 and low TIL density were associated with poor biochemical relapse-free survival (BRFS) (p ≤ 0.006). In multivariate analysis, TIL density, but not LDH5, was an independent predictor of BRFS (p = 0.03). Conclusions: LDH5 overexpression is associated with low tumor lymphocytic infiltration. Stratifying prostate carcinomas according to LDH5/TIL density identifies a group of patients with low TIL density and high LDH5 expression, who have a higher risk of tumor relapse. Targeting glycolysis to disrupt cancer cell metabolism offers an interesting research area for prostate cancer therapy.
- Open Access
Autophagy-Related Proteins’ Immunohistochemical Expression and Their Potential Role as Biomarkers in Thymic Epithelial Tumors
Background: Autophagy, a self-destructive cellular mechanism with a paradoxical nature, plays a part in both tumor suppression and induction by providing cancer cells with metabolic substrates, resulting in cell proliferation and survival. In this study, we aim to investigate the clinical significance of four autophagy pathway components (BECLIN, p62/, LC3b, ATG3) in pathogenetic mechanisms of thymic epithelial tumors (TETs) with possible prognostic importance. Methods: Immunohistochemistry was used to evaluate the cytoplasmic expression of BECLIN, p62, LC3b, and ATG3 in tumor cells of 99 TETs, and possible correlations with clinicopathological parameters were examined. Results: Higher BECLIN and p62 expression was associated with male gender (p = 0.027 and p = 0.014, respectively). B3 thymomas and thymic carcinomas (TCs) displayed higher p62 expression (p = 0.019), while LC3b expression was marginally higher in non-B3/TC TETs (p = 0.098). A positive correlation between higher BECLIN expression and advanced Masaoka–Koga stage was also observed (p = 0.009). ATG3 was not associated with any of the investigated clinicopathological parameters (p > 0.05). There was also no significant correlation between any of the four examined molecules and overall survival or relapse. Conclusions: Our findings indicate autophagy activation in B3/TC and advanced Masaoka–Koga stage cases. Further studies are needed to explore the role of these autophagy related proteins as potential biomarkers and therapeutic targets in TETs.
Open AccessAutophagy-Related Proteins’ Immunohistochemical Expression and Their Potential Role as Biomarkers in Thymic Epithelial Tumors
Background: Autophagy, a self-destructive cellular mechanism with a paradoxical nature, plays a part in both tumor suppression and induction by providing cancer cells with metabolic substrates, resulting in cell proliferation and survival. In this study, we aim to investigate the clinical significance of four autophagy pathway components (BECLIN, p62/, LC3b, ATG3) in pathogenetic mechanisms of thymic epithelial tumors (TETs) with possible prognostic importance. Methods: Immunohistochemistry was used to evaluate the cytoplasmic expression of BECLIN, p62, LC3b, and ATG3 in tumor cells of 99 TETs, and possible correlations with clinicopathological parameters were examined. Results: Higher BECLIN and p62 expression was associated with male gender (p = 0.027 and p = 0.014, respectively). B3 thymomas and thymic carcinomas (TCs) displayed higher p62 expression (p = 0.019), while LC3b expression was marginally higher in non-B3/TC TETs (p = 0.098). A positive correlation between higher BECLIN expression and advanced Masaoka–Koga stage was also observed (p = 0.009). ATG3 was not associated with any of the investigated clinicopathological parameters (p > 0.05). There was also no significant correlation between any of the four examined molecules and overall survival or relapse. Conclusions: Our findings indicate autophagy activation in B3/TC and advanced Masaoka–Koga stage cases. Further studies are needed to explore the role of these autophagy related proteins as potential biomarkers and therapeutic targets in TETs.
- Open Access
- 2 January 2026
- Published by International Institute of Anticancer Research in In Vivo
- Vol. 40 (1) , 411-421
Immunohistochemical Analysis of IRE1 and PERK Expression in Extravillous Trophoblast Cells of Placenta Accreta Spectrum and Associations With Clinicopathological Parameters
Background/Aim: Placenta accreta spectrum (PAS) is characterized by abnormal placental adherence/invasion at a scarred implantation bed. Endoplasmic reticulum (ER) stress signaling via inositol-requiring enzyme 1 (IRE1) and protein kinase RNA-like endoplasmic reticulum kinase (PERK) shapes trophoblast behavior, but its interface-specific role in PAS is unclear. We evaluated IRE1 and PERK immunoreactivity in extravillous trophoblast (EVT) subsets to test associations with PAS severity and maternal outcomes. Patients and Methods: In a retrospective series from a tertiary center, cesarean hysterectomy specimens for PAS and gestational age-matched cesarean controls were analyzed. Immunohistochemistry for IRE1 and PERK was performed on basal plate regions, with semiquantitative immunoreactivity score (IRS:0-12) recorded for EVT subtypes. Associations with clinicopathological parameters and with negative controls were examined with bivariate analyses. Results: IRE1 expression showed no significant associations with clinicopathological parameters. PERK IRS was significantly higher in PAS obstetrical hysterectomy specimens than in controls (mean 9.40±1.96 vs. 4.17±1.52; pp=0.035). Conclusion: PERK-IRS was elevated at the stressed implantation interface in PAS relative to normal placentation, while IRE1 showed no clear differential signal with the current assay. Paradoxically, within PAS, lower local PERK-IRS signal correlated with complications, suggesting that the magnitude/timing of PERK engagement may influence operative risk. Larger studies incorporating activation-specific markers are warranted to refine biological stratification and prognostication in PAS.
- 2 January 2026
- Published by International Institute of Anticancer Research in In Vivo
- Vol. 40 (1) , 411-421
Open AccessImmunohistochemical Analysis of IRE1 and PERK Expression in Extravillous Trophoblast Cells of Placenta Accreta Spectrum and Associations With Clinicopathological Parameters
Background/Aim: Placenta accreta spectrum (PAS) is characterized by abnormal placental adherence/invasion at a scarred implantation bed. Endoplasmic reticulum (ER) stress signaling via inositol-requiring enzyme 1 (IRE1) and protein kinase RNA-like endoplasmic reticulum kinase (PERK) shapes trophoblast behavior, but its interface-specific role in PAS is unclear. We evaluated IRE1 and PERK immunoreactivity in extravillous trophoblast (EVT) subsets to test associations with PAS severity and maternal outcomes. Patients and Methods: In a retrospective series from a tertiary center, cesarean hysterectomy specimens for PAS and gestational age-matched cesarean controls were analyzed. Immunohistochemistry for IRE1 and PERK was performed on basal plate regions, with semiquantitative immunoreactivity score (IRS:0-12) recorded for EVT subtypes. Associations with clinicopathological parameters and with negative controls were examined with bivariate analyses. Results: IRE1 expression showed no significant associations with clinicopathological parameters. PERK IRS was significantly higher in PAS obstetrical hysterectomy specimens than in controls (mean 9.40±1.96 vs. 4.17±1.52; pp=0.035). Conclusion: PERK-IRS was elevated at the stressed implantation interface in PAS relative to normal placentation, while IRE1 showed no clear differential signal with the current assay. Paradoxically, within PAS, lower local PERK-IRS signal correlated with complications, suggesting that the magnitude/timing of PERK engagement may influence operative risk. Larger studies incorporating activation-specific markers are warranted to refine biological stratification and prognostication in PAS.
- Open Access
- 5 September 2025
- Published by Springer Nature in Cureus
- Vol. 17 (9)
A Case Report of a Giant Placental Chorioangioma: Prenatal Diagnosis and Perinatal Outcome
Chorioangiomas are benign placental vascular tumors, most commonly detected during antenatal ultrasound screening. While small lesions are often clinically insignificant, giant chorioangiomas defined as those exceeding 4 cm in diameter can be associated with serious fetal and maternal complications, including fetal anemia, thrombocytopenia, fetal heart failure, fetal hydrops, placentomegaly, polyhydramnios, maternal mirror syndrome, fetal demise, and neonatal death. Doppler ultrasound and magnetic resonance imaging aid in differentiating these tumors from other placental lesions. Treatment is tailored according to gestational age, tumor size, and associated complications. Small asymptomatic lesions may require only routine surveillance, whereas large or symptomatic chorioangiomas can necessitate interventions such as intrauterine transfusion, amnioreduction, or more advanced procedures like fetoscopic-assisted ablation or embolization. We present the case of a 30-year-old primigravida (G1P0) diagnosed with a large placental chorioangioma and polyhydramnios at 28 weeks of gestation during a routine growth ultrasound, who was referred to our tertiary care center for further management. The patient underwent two ultrasound-guided amnioreduction procedures for symptomatic polyhydramnios. At 31 weeks of gestation, she experienced preterm premature rupture of membranes (PPROM), followed by spontaneous labor, and subsequently delivered via cesarean section. A preterm neonate was born with favorable immediate postnatal outcomes. This case underscores the importance of early diagnosis and individualized, timely management in reducing fetal and maternal morbidity and mortality associated with large placental chorioangiomas. By detailing the diagnostic challenges and therapeutic decisions in a case complicated by polyhydramnios, this report aims to contribute meaningful insight to the existing literature.
- 5 September 2025
- Published by Springer Nature in Cureus
- Vol. 17 (9)
Open AccessA Case Report of a Giant Placental Chorioangioma: Prenatal Diagnosis and Perinatal Outcome
Chorioangiomas are benign placental vascular tumors, most commonly detected during antenatal ultrasound screening. While small lesions are often clinically insignificant, giant chorioangiomas defined as those exceeding 4 cm in diameter can be associated with serious fetal and maternal complications, including fetal anemia, thrombocytopenia, fetal heart failure, fetal hydrops, placentomegaly, polyhydramnios, maternal mirror syndrome, fetal demise, and neonatal death. Doppler ultrasound and magnetic resonance imaging aid in differentiating these tumors from other placental lesions. Treatment is tailored according to gestational age, tumor size, and associated complications. Small asymptomatic lesions may require only routine surveillance, whereas large or symptomatic chorioangiomas can necessitate interventions such as intrauterine transfusion, amnioreduction, or more advanced procedures like fetoscopic-assisted ablation or embolization. We present the case of a 30-year-old primigravida (G1P0) diagnosed with a large placental chorioangioma and polyhydramnios at 28 weeks of gestation during a routine growth ultrasound, who was referred to our tertiary care center for further management. The patient underwent two ultrasound-guided amnioreduction procedures for symptomatic polyhydramnios. At 31 weeks of gestation, she experienced preterm premature rupture of membranes (PPROM), followed by spontaneous labor, and subsequently delivered via cesarean section. A preterm neonate was born with favorable immediate postnatal outcomes. This case underscores the importance of early diagnosis and individualized, timely management in reducing fetal and maternal morbidity and mortality associated with large placental chorioangiomas. By detailing the diagnostic challenges and therapeutic decisions in a case complicated by polyhydramnios, this report aims to contribute meaningful insight to the existing literature.
- Open Access
- 29 May 2025
- Published by Springer Nature in Cureus
- Vol. 17 (5)
Placenta Percreta Previa Crossing Surgical Frontiers
Placenta percreta represents a severe form of placenta accreta spectrum (PAS), characterized by the full-thickness invasion of placental villi through the uterine wall, often extending into adjacent structures. Its incidence is rising in parallel with the increased rates of cesarean sections and uterine interventions. We report a case involving a patient 37+6 weeks of gestation with a history of four cesarean sections and inadequate prenatal surveillance that was admitted with symptoms of labor onset. Intraoperatively, the placenta was found to invade not only the myometrium but also the parametrial tissue and uterine arteries, complicating the surgical field. An emergency cesarean section was performed, resulting in the delivery of a neonate in excellent health. However, due to massive hemorrhage and extensive local invasion, the patient required a radical hysterectomy with bilateral salpingo-oophorectomy, alongside multiple reoperations to address ensuing complications such as hemoperitoneum and uroperitoneum. The complexity of the case necessitated prompt multidisciplinary intervention, including hemostatic techniques, urological interventions and vigilant perioperative care. Administration to ICU, multidisciplinary management, encompassing renal support, urinary bladder repair, temporary nephrostomies, management of hospital infections, structured physiotherapy and speech therapy were crucial in stabilizing the patient and facilitating gradual recovery. Placenta percreta with parametrial and uterine artery invasion is a challenging clinical scenario that demands early diagnosis and coordinated multidisciplinary management. Optimizing prenatal screening protocols and surgical preparedness is essential to mitigate the high risks of maternal morbidity and mortality associated with this condition.
- 29 May 2025
- Published by Springer Nature in Cureus
- Vol. 17 (5)
Open AccessPlacenta Percreta Previa Crossing Surgical Frontiers
Placenta percreta represents a severe form of placenta accreta spectrum (PAS), characterized by the full-thickness invasion of placental villi through the uterine wall, often extending into adjacent structures. Its incidence is rising in parallel with the increased rates of cesarean sections and uterine interventions. We report a case involving a patient 37+6 weeks of gestation with a history of four cesarean sections and inadequate prenatal surveillance that was admitted with symptoms of labor onset. Intraoperatively, the placenta was found to invade not only the myometrium but also the parametrial tissue and uterine arteries, complicating the surgical field. An emergency cesarean section was performed, resulting in the delivery of a neonate in excellent health. However, due to massive hemorrhage and extensive local invasion, the patient required a radical hysterectomy with bilateral salpingo-oophorectomy, alongside multiple reoperations to address ensuing complications such as hemoperitoneum and uroperitoneum. The complexity of the case necessitated prompt multidisciplinary intervention, including hemostatic techniques, urological interventions and vigilant perioperative care. Administration to ICU, multidisciplinary management, encompassing renal support, urinary bladder repair, temporary nephrostomies, management of hospital infections, structured physiotherapy and speech therapy were crucial in stabilizing the patient and facilitating gradual recovery. Placenta percreta with parametrial and uterine artery invasion is a challenging clinical scenario that demands early diagnosis and coordinated multidisciplinary management. Optimizing prenatal screening protocols and surgical preparedness is essential to mitigate the high risks of maternal morbidity and mortality associated with this condition.